What is comprehensive genomic profiling?
Comprehensive genomic profiling (CGP) is a tumor testing method performed on multiple specimen types including tissue, isolated nucleic acids and blood, that uses next-generation sequencing (NGS) technology to detect the four main classes of alterations known to drive cancer growth, and to identify genomic signatures and alterations that may predict response, or lack thereof, to certain therapies. Comprehensive genomic profiling enables the practice of precision medicine by informing individualized treatment decisions for the management of all types of cancer.
How is comprehensive genomic profiling different from single-gene ("hot spot") testing for solid tumors?
Single-gene testing identifies only one or two classes of genomic alterations. Comprehensive genomic profiling (CGP) approach identifies four classes of genomic alterations: base substitutions, insertions and deletions/indels, copy number alterations, and rearrangements.
Who is eligible for the tests?
Any patient with a solid tumor, hematologic malignancy, or sarcoma is eligible for our tests.
Whom can I contact with additional questions?